Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway.

Bioscience Reports
Zheng WangZhanzheng Zhao

Abstract

To investigate whether the human anti-thrombospondin type 1 domain-containing 7A (THSD7A) antibody-induced membranous nephropathy (MN) is mediated by activating lectin complement pathway. Automatic biochemical apparatus was used to assess renal function of mice. The serum levels of anti-THSD7A antibodies and complement were tested by using ELISA. The expression level of THSD7A and mannose-binding lectin (MBL) in clinical tissue, and the histological features of MN in mice were examined by immunochemical methods. We found that THSD7A, MBL, and complement expression level from patients with circulating anti-THSD7A antibodies were significantly higher than that in normal group. Furthermore, difference of renal function in anti-THSD7A antibody-containing serum treatment groups and control groups was significant. Meanwhile, human anti-THSD7A autoantibodies activated the complement system and induced the histological features of MN in mice. In conclusion, human anti-THSD7A antibodies induce MN through activating MBL lectin complement pathway in mice.

References

Dec 1, 1978·The Journal of Clinical Investigation·W G CouserL M Lowenstein
Aug 31, 2007·Drugs & Aging·Jeroen K J Deegens, Jack F M Wetzels
Sep 18, 2007·Science·Marijn van der Neut KolfschotenPaul W H I Parren
Jul 3, 2009·The New England Journal of Medicine·Laurence H BeckDavid J Salant
Jan 30, 2010·Journal of the American Society of Nephrology : JASN·Natalia PolancoUNKNOWN Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología
Feb 18, 2011·The New England Journal of Medicine·Hanna Debiec, Pierre Ronco
Feb 23, 2013·Journal of the American Society of Nephrology : JASN·Marieke J H CoenenPierre Ronco
Sep 12, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Sjoerd A M E G TimmermansUNKNOWN Limburg Renal Registry
Oct 1, 2013·Autoimmunity Reviews·Wolfgang SchlumbergerWinfried Stöcker
Oct 29, 2013·Seminars in Nephrology·Hong MaLaurence H Beck
Mar 13, 2014·Journal of the American Society of Nephrology : JASN·Elion HoxhaRolf A K Stahl
Jun 4, 2014·The Journal of Clinical Investigation·Laurence H Beck, David J Salant
Jun 11, 2015·The New England Journal of Medicine·Shreya KangoviChau Trinh-Shevrin
May 24, 2016·The Journal of Clinical Investigation·Nicola M TomasRolf A K Stahl

❮ Previous
Next ❯

Citations

Nov 16, 2018·Expert Review of Clinical Immunology·Rolf Ak StahlElion Hoxha
May 22, 2020·Journal of Translational Internal Medicine·Rui LangRenhuan Yu
Jan 1, 2020·International Journal of Molecular Sciences·Sofia AndrighettoPaolo Cravedi
Mar 19, 2020·Molecular Medicine Reports·Han Xue JiangWei Jing Liu
Feb 23, 2020·Journal of Immunology Research·Maël LatebBarbara Seitz-Polski
Apr 4, 2021·Biomolecules·Yan GuDamu Tang
Apr 30, 2021·Néphrologie & thérapeutique·Jens Lutz
Sep 18, 2021·Clinical Science·Erika I Boesen, Rahul M Kakalij

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
ELISA

Software Mentioned

SPSS
ImagePro Plus

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.